ZA200105304B - Method and kit for extracting prion protein. - Google Patents
Method and kit for extracting prion protein. Download PDFInfo
- Publication number
- ZA200105304B ZA200105304B ZA200105304A ZA200105304A ZA200105304B ZA 200105304 B ZA200105304 B ZA 200105304B ZA 200105304 A ZA200105304 A ZA 200105304A ZA 200105304 A ZA200105304 A ZA 200105304A ZA 200105304 B ZA200105304 B ZA 200105304B
- Authority
- ZA
- South Africa
- Prior art keywords
- prion protein
- abnormal prion
- lyotropic
- extraction solvent
- biological
- Prior art date
Links
- 108091000054 Prion Proteins 0.000 title claims description 183
- 102000029797 Prion Human genes 0.000 title claims description 181
- 238000000034 method Methods 0.000 title claims description 64
- 230000002159 abnormal effect Effects 0.000 claims description 108
- 238000000605 extraction Methods 0.000 claims description 78
- 239000002904 solvent Substances 0.000 claims description 61
- 230000002535 lyotropic effect Effects 0.000 claims description 53
- 239000012620 biological material Substances 0.000 claims description 47
- 238000002360 preparation method Methods 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 38
- 238000003556 assay Methods 0.000 claims description 33
- 239000007864 aqueous solution Substances 0.000 claims description 28
- 241001465754 Metazoa Species 0.000 claims description 22
- 238000003018 immunoassay Methods 0.000 claims description 22
- 239000000523 sample Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- 239000012472 biological sample Substances 0.000 claims description 19
- 238000002013 hydrophilic interaction chromatography Methods 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 15
- 210000001519 tissue Anatomy 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical group FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims description 12
- 108010067770 Endopeptidase K Proteins 0.000 claims description 12
- 239000013060 biological fluid Substances 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 11
- 238000011534 incubation Methods 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 9
- 239000003495 polar organic solvent Substances 0.000 claims description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 9
- 235000011152 sodium sulphate Nutrition 0.000 claims description 9
- 239000008188 pellet Substances 0.000 claims description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 7
- 238000005251 capillar electrophoresis Methods 0.000 claims description 7
- 239000012266 salt solution Substances 0.000 claims description 6
- 210000005013 brain tissue Anatomy 0.000 claims description 5
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 238000002331 protein detection Methods 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 241001494479 Pecora Species 0.000 description 20
- 239000000463 material Substances 0.000 description 20
- 208000010544 human prion disease Diseases 0.000 description 17
- 210000004556 brain Anatomy 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 208000008864 scrapie Diseases 0.000 description 11
- 239000000284 extract Substances 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 238000005191 phase separation Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 8
- 208000024777 Prion disease Diseases 0.000 description 7
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000003398 denaturant Substances 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000019833 protease Nutrition 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000000760 immunoelectrophoresis Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000001155 isoelectric focusing Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 230000000389 anti-prion effect Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000007818 agglutination assay Methods 0.000 description 2
- 238000012863 analytical testing Methods 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 238000000533 capillary isoelectric focusing Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 244000144992 flock Species 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- -1 perfluoro-t-butyl Chemical group 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ZVXAXABPTOPGDK-UHFFFAOYSA-N 1,1,1,3,3,4,4,4-octafluorobutan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)C(F)(F)F ZVXAXABPTOPGDK-UHFFFAOYSA-N 0.000 description 1
- GILIYJDBJZWGBG-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-ol Chemical compound CC(O)C(F)(F)F GILIYJDBJZWGBG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000282979 Alces alces Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000010624 Medicago sativa Nutrition 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 241000282943 Odocoileus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101800001295 Putative ATP-dependent helicase Proteins 0.000 description 1
- 101800001006 Putative helicase Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000006177 biological buffer Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000001818 capillary gel electrophoresis Methods 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000007813 chromatographic assay Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003017 in situ immunoassay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 1
- 239000002900 solid radioactive waste Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Description
METHOD AND KIT FOR EXTRACTING PRION PROTEIN
The present invention relates to a method for extracting prion protein from a biological material, such as, for example, an animal tissue or a biological fluid. The extraction process permits testing for the presence of abnormal prion protein, e.g., for diagnosis of transmissible spongiform encephalopathies.
Prion diseases or transmissible spongiform encephalopathies (TSBs) cause progressive degenerative disorders of the central nervous system resulting in death (Prusiner, Med. Res. Rev. 16:487, 1996; Weissman, FEBS Letters 289:3, 1996). Scrapie, a TSE } in sheep, was first described over 200 years ago (Pattison, Vet. ) Rec. 123:661, 1988), and is the prototype of these diseases.
There are no known treatments for these diseases and no known : antemortem tests for the presence of the disease in an animal.
Prion diseases are caused by a conformational change of the normal host prion protein to an abnormal structure that forms aggregates.
Because of the recent outbreak of bovine spongiform encephalopathy in the United Kingdom and the connection between this TSE and the new variant, Creutzfeld-Jakob (Bruce et al., Nature 389:498, 1997), a human TSE, there is a need for new methods that are both sensitive and accurate to diagnose TSEs. Ideally, this diagnosis could be used to test animals before they show clinical signs and before they enter the human food chain or into pharmaceuticals prepared for human use. —_—
Description of the Prior Art
Most of the methods used to prepare and purify the disease- causing agents of TSEs involve a complex sequence of enzyme and detergent treatments and centrifugations (Bolton et al., J. Virol. 53:596, 1985). Abnormal prion protein is poorly soluble in the typical biological buffers. One method for obtaining purified abnormal prion protein is hydrophilic interaction chromatography (HILIC) (Alpert, J., Chromatogr. 499:177, 1990), which is the inverse of reversed-phase chromatography. Typically, one starts with 70-85% organic solvent and runs a decreasing organic gradient. Elution is in the order of least to most polar. The mostly organic mobile phases of HILIC are compatible with proteins not normally occurring free in aqueous sclution, such as membrane proteins (Jend et al., Anal. Biochem. 215:292, 1993), p-amyloid peptide (1-43) (Alpert et al., Eighth Symposium of the Protein
Society, July 1994, San Diego, CA), and histones (Lindner et al., .
J. Chromatogr. A. 782:55, 1997). Surfactants and other denaturants elute in or near the void volume, while proteins and } peptides are generally well-retained.
After HILIC purification, the prion protein can be detected using capillary electrophoresis immunoassay (Schmerr and Jenny,
Electrophoresis 19:409, 1998) or by capillary isoelectric focusing (schmerr et al., J. Chromatogr. A. 802:135, 1998).
As noted above, present analytical methods to detect abnormal prion protein generally are used post mortem, thus there is a need for an antemortem assay for abnormal prion protein. In addition, a method is required for isolation of abnormal prion protein without ultracentrifugation steps, which require instrumentation that is not readily available to veterinary diagnostic laboratories. Centrifugation requires the presence of abnormal prion protein as aggregates, whose large size facilitates pellet
: 9! WO 00/40966 PCT/US00/00457 formation in the centrifuge tubes. Such aggregates are difficult to dissolve and detect in subsequent steps. The use of centrifugation also jeopardizes the possibility of detecting monomeric abnormal prion protein, potentially decreasing the sensitivity of any assay. There is an even more pressing need for a fast, reliable field assay, such as a qualitative immunoassay, to test livestock for infection with a TSE. Thus, there is a need in the art for an efficient, simple method for extracting abnormal prion protein.
Additionally, the antibodies that have been produced detect abnormal prion protein in its monomeric form, with the exception of the antibody produced to the native abnormal prion protein (Korth et al., Nature 390:74, 1997). As a result, abnormal prion protein must be deaggregated with strong detergents or denaturants; these denaturants must then be removed before ] performing most immunoassays. Thus, there is a need in the art for a rapid, simple method to extract prion protein free of . detergents or denaturants for immunoassay analysis.
The present invention provides a new method for the extraction of all sizes of the abnormal prion protein, whether in aggregated or monomeric form. The invention makes it possible to test for abnormal prion protein in samples from a live animal, e.g., using immunoassays. For example, diagnosis can be based on blood samples, which will allow for the testing of live animals and facilitate the removal of infected animals from flocks and herds, and prevent possible contamination of products for consumption.
The invention provides a method for extracting abnormal prion ) protein from a biological material suspected of containing abnormal prion protein. The method comprises incubating a mixture of extraction solvent and an isotonic or hypotonic aqueous preparation of the biological material under conditions effective to extract abnormal prion protein from the biological material into the extraction solvent. The extraction solvent is a polar organic solvent in which the abnormal prion protein is soluble, and it is miscible with a hypotonic or isotonic aqueous solution but immiscible with a 1lyotropic aqueous solution. Lyotropic activity of the mixture is increased so that the extraction solvent separates as a distinct phase from the aqueous preparation of the biological material to yield extraction solvent containing any abnormal prion protein from the biological material.
The invention further provides a method for detecting the presence of abnormal prion protein in an animal, comprising assaying a separated extraction solvent prepared as described above for abnormal prion protein.
Also provided is a kit for isolating abnormal prion protein from a biological sample. The kit comprises an extraction i solvent, which has the characteristics set forth above, and a ) lyotropic salt or aqueous lyotropic salt sclution to add to an aqueous preparation of a biological sample so that the organic solvent becomes immiscible with the aqueous preparation. In another embodiment of the invention, the kit includes a prion protein detection assay, preferably an assay for an abnormal prion protein.
Thus, it is an object of the invention to provide a rapid method for isolating abnormal prion protein from a biological sample.
It is also an object of the invention to provide an early detection method for organisms infected with abnormal prion protein.
: 1 y, WO 00/40966 PCT/US00/00457
Tt is a further object of the invention to provide a solvent extraction technique for isolating abnormal prion protein from a biological sample.
Still another object of the invention is to simplify analytical testing of a biological material from an animal or human for the presence of abnormal prion protein.
Yet another object of the invention is to provide an extract containing abnormal prion protein for further testing or purification.
These and other objects of the invention are presented in greater detail in the accompanying Drawings and Detailed
PIG. 1. Chromatogram from HILIC of **I-prion protein, as } detected by radioactivity (open circles) and by absorbance at 280 nm (solid line). ] FIG. 2. Antibody binding of HILIC factions of **I-prion protein.
The present invention provides a method for extracting abnormal prion protein from biological material. The extracted product can be tested by an immunoassay for the abnormal prion protein. This extraction of abnormal prion protein, in conjunction with an immunoassay, can be used to diagnose living organisms for infection with a TSE, and will be of worldwide use for testing for TSE infected animals and humans. Thus, the present invention advantageously permits testing for prion protein in clinics and veterinary labs that lack expensive centrifuges, and further permits testing in the field.
Ce
An aqueous preparation of the biological material is combined with an extraction solvent to form a mixture. The extraction solvent is a polar organic solvent in which abnormal prion protein is soluble, and miscible with a non-lyotropic isotonic aqueous solution but immiscible with a lyotropic aqueous solution. In a specific preferred embodiment, the extraction solvent is hexafluoro-2-propanol (also termed hexafluoroisopropanol or HFIP).
Although in the examples, infra, the volumes of extraction buffer and aqueous preparation of biological material are about equal, any ratio can be used that yields two distinct phases, as described below.
In a preferred embodiment, the mixture is incubated at a temperature ranging from about 20°C to about 100%C. Nevertheless, any temperature at which both the extraction solvent and aqueous preparation of biological material are in a liquid phase, i.e., between the freezing point and the boiling point, can be used. .
The extraction solvent-biological material mixture is incubated under conditions effective to extract abnormal prion ) protein from the biological material into the extraction solvent.
After incubation, the lyotropic activity of the mixture is increased so that the extraction solvent separates from the aqueous preparation. The extraction solvent containing prion protein is removed from the aqueous preparation of biological material.
According to the invention, the lyotropic activity of the extraction solvent-aqueous preparation can be increased by adding a lyotropic salt. The salt can be added as a solid directly to the mixture, or as a concentrated aqueous solution. Preferred examples of lyotropic salts include sodium sulfate and ammonium sulfate. In a specific embodiment, exemplified infra, the ionic )
: LV. WO 00/40966 PCT/US00/00457 strength is increased by adding about a 1:1 ratio (vol/vol) of 0.5
M sodium sulfate to the mixture.
The invention is particularly advantageous because it does not require obtaining material from autopsy or necropsy.
According to the invention, the biological material can be a sample from a living animal. The method of the invention provides for extraction of abnormal prion protein from a biological fluid or organ biopsy for analytical testing. Alternatively, the biological material can be obtained from an autopsy Or necropsy, e.g., of animal products to be used for food, pharmaceutical, cosmetic, or other products for use by humans or with other animals. In a further embodiment, the method of the invention can be used to remove prion protein from such materials to ensure that infectious prions are not transmitted. " The extraction method of the invention can be used to extract - both normal prion protein and abnormal prion protein. By pretreating the biological sample with proteinase-K, the normal . prion protein can be digested. Thus, where only abnormal prion protein is desired, the aqueous preparation of biological material can be pre-treated with proteinase-K prior to mixing it with the extraction solvent.
The extraction solution containing any prion protein can be dried to yield an extractant pellet. Prion protein in the solution or extractant pellet can be further purified, e.g., by hydrophilic interaction chromatography.
Abnormal prion protein in an animal can be detected by assaying material in the separated extractant pellet for its presence. Preferably, the assay method is an immunoassay for abnormal prion protein. The sample can be treated with proteinase-K prior to isolation of the prion protein so that no normal prion protein is isolated.
In another aspect, the invention provides kits for isolating abnormal prion protein from a biological sample. In one embodiment, a kit comprises extraction solvent, e.g., hexafluoro- 2-propanol. The kit further comprises a lyotropic salt or aqueous lyotropic salt solution to add to an aqueous preparation of a biclogical sample 80 that the extraction solvent becomes immiscible with the aqueous preparation.
The invention further provides a kit for detecting the presence of abnormal prion protein from a biological sample. In addition to the kit components described above, the detection kit includes a detection assay for abnormal prion protein. The preferred detection assay for the presence of abnormal prion protein is an immunoassay.
Although this extraction method and kit have been developed primarily for the diagnosis of scrapie (TSE in sheep), they are useful for diagnosis of other TSEs in other vertebrates, . particularly in mammalian animals and avians, such as humans, bovines, swine, elk, deer, poultry, and rodents. Abnormal prion ] protein can be detected in tissue of animals and humans as early as two weeks after infection. A significant application of the process of this invention is detection of abnormal prion protein in human blood. This technique can also be used for extraction of the abnormal prion protein from process material used to produce human pharmaceuticals or other products intended for human use, including food supplements.
As used herein, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.
Biological Materials
The present invention permits the extraction of prion protein from a biological material. Generally, prion proteins are found in vertebrates, as discussed above. Therefore, under most circumstances, the biological material will be from an animal or human. Prion protein can also be produced during fermentation processes with eukaryotic cells. It may be expressed as a recombinant prion protein. Of greater concern is the possibility of incidental expression of endogenous prion protein by cells that have been recombinantly modified to express another protein. This possibility is more likely if the cells are of neural origin, such as PC12 cells. In this case, the biological material may be a fermentation product, e.g., recombinant protein.
Examples of biological materials from animals include, but are by no means limited to, tissues, such as brain, muscle (including heart), liver, appendix, pancreas, gastrointestinal tract organs, skin, and lymphoid tissue, such as thymus, spleen, tonsil, lymph nodes, etc. Alternatively, the biological material may be a biological fluid. The term biological fluid refers to cerebrospinal fluid, blood, serum, plasma, milk, urine, saliva, tears, mucous secretions, sweat, semen and bodily fluids comprising these components. It also refers to culture fluid (or culture medium) used in the production of recombinant proteins or containing cells in suspension prior to transplantation. Also encompassed by the term “biological materials” are products made from animal organs or tissues, including serum proteins (such as albumin and immunoglobulin), hormones, food and processed food products, nutritional supplements, bone meal, animal feed, extracellular matrix proteins, gelatin, and other animal by- products used in manufacturing or final goods. —_
Where the biological material is a solid tissue or product, a it must first be dissolved or suspended in an aqueous solution so that it will be suitable for the extraction process. For example, brain tissue may be suspended in sucrose solution (e.g., 0.32 M sucrose) at 10% weight to volume. Other hypotonic or isotonic solutions include 5% dextrose, phosphate buffered saline, tri- buffered saline, HEPES-buffered saline, or any of the foregoing buffers. The biological material in the aqueous solution can also be homogenized, ground, or otherwise disrupted to maximize contact between the extraction solvent and the biological material.
However, if a biological fluid is the biological material, addition of liquid is not likely to be necessary, unless to dilute the ionic strength of the biological fluid to permit miscibility of the extraction solvent.
Prion Protein )
The term "prion protein" as used herein refers to a native n protein expressed in neural tissue, particularly the brain and at } lower levels in lymphoid tissues and all other tissues. Under some circumstances, prion protein adopts a pathogenic conformation, which is termed herein abnormal prion protein.
Certain mutations of the prion gene in some individuals appear to predispose prion protein to adopt the pathogenic conformation.
Exposure of an organism to a transmissible infectious agent, the prion, can also induce the conformational change leading to the pathology.
Abnormal prion protein is much less susceptible to proteolysis than normal prion protein. Treatment of a biological material with a proteinase, particularly proteinase-K, digests normal prion protein, but not abnormal prion protein. —
; [4 WO 00/40966 PCT/US00/00457
In specific examples, infra, sheep abnormal prion protein (PrP**) is extracted by the method of the invention. However, other prion proteins from other species, particularly those mentioned above, can also be extracted using the method of the invention.
Included in the category of abnormal prion protein are human prion proteins found in the neurodegenerative diseases Kuru,
Creutzfeld-Jakob Disease (CJD), Gerstmann-Straussler Syndrome (GSS), and fatal familial insomnia. Some case of CJD and GSS are associated with known mutations of the prion gene. CJD is also associated with exposure to TSEs. For example, as noted above,
CJD has been associated with bovine spongiform encephalopathy. The present invention permits, for the first time, extraction of abnormal prion protein in patients prior to autopsy. Detection of extracted abnormal prion protein can be used in the diagnosis . of any of these diseases.
Scrapie (sheep, goats) and bovine spongiform encephalopathy ] (cows) are abnormal prion diseases of animals. Prion proteins have also been isolated in chicken, mink, pigs, mouse, hamster, and guinea pig. Furthermore, mouse, hamster, and guinea pig can develop a spongiform encephalopathy by exposure to prions from human or other animal sources. Prion protein from any of these sources can be detected or extracted by the method of the invention.
Extraction Solvent and Conditions
An extraction solvent for use in the present invention must be capable of separating as a distinct phase from water or an aqueous solution under lyotropic conditions. At the same time, prion protein must be soluble in the extraction solvent. Some 3 polar organic solvents meet these criteria. The preferred polar organic solvent is hexafluoro-2-propanol. Other solvents that can be used include isopropanol; 1,1,1-trifluoro-2-propanol (TFIP); 2,2,3,3-tetrafluoro-1i-propanol (tetF1pP); perfluoro-t-butyl alcohol (PFtBA) ; 1,1,1,3,3,3-hexafluoroacetone (HFA) ; trifluoroacetic acid (TFA); 2,2,2-trifluoro-l-ethanol (TFE); 2,2,3,3,4,4,4-heptafluoro-2-propanol (HFB) ; 1,1,1,3,3,4,4,4- octafluoro-2-butanol (OFIB); l-methyl-2-pyrrolidinone (NMP); see
Wille et al., J. Mol. Biol., 259:608, 1996. Other possible solvents that can be evaluated include DMSO; tetrahydrofuran; and the like. Alternatively, a solvent that is not miscible with water, but in which prion protein is soluble, could be used.
In a specific embodiment, the solvent is miscible with water, e.g., at physiological ionic strength (isotonic aqueous solution) or lower than physiological ionic strength (hypotonic aqueous solution). However, when the buffer comprises lyotropic salts present at a concentration (or ionic strength) above a threshold . value, the extraction solvent is not soluble in the aqueous solution: the two phases separate into an extraction solvent layer } and an aqueous solution layer. These are referred to herein as "lyotropic conditions". The value for ionic strength of a lyotropic salt of the aqueous solution which achieves lyotropic conditions can vary depending on the extraction solvent selected and the salt (s) used. It can be readily determined by titration or other systematic variation of lyotropic salt concentration, with testing for miscibility or immiscibility of the extraction solvent with the aqueous solution. As used herein, an aqueous solution with an ionic strength of a lyotropic salt at which the extraction solvent separates from water is referred to as a lyotropic aqueous solution. Aqueous solutions containing lower concentrations of lyotropic salts or physiological salts, such as isotonic buffers, are considered non-lyotropic solutions.
: wr WO 00/40966 PCT/US00/00457
Generally, about equal volumes of an extraction solvent and the aqueous preparation of a biological material are used in a solvent extraction process. However, the ratio of extraction solvent to aqueous preparation can range from about 5:1 to about 1:5, preferably from about 3:1 to about 1:3.
After mixing the extraction solvent with the aqueous preparation, the mixture can be incubated for some period of time and at a particular temperature to enhance extraction of prion : protein into the extraction buffer. The incubation time can vary from 1 minute to hours, and can be determined by analyzing the extracted material for the presence of prion protein. After the amount of prion protein in the extraction material versus time reaches a plateau, which can be tested using chromatographic or immunoassay techniques, or both, as described in the Examples, additional incubation will have no effect on the prion protein - yield. In a specific embodiment, the incubation time is 5 minutes. . In addition, the temperature of incubation can be adjusted to increase the efficiency of extraction, provided that the extraction solvent and aqueous solution are both liquids at the selected temperature. Warmer temperatures, i.e., above room temperature, are preferred, since they increase the solubility of prion protein in the extraction solvent. Particularly useful are temperatures within the range of about 50°C-60°C. As with other variables, such as the ionic strength of the aqueous preparation and time of incubation, an optimal temperature can be determined by routine experimentation and testing.
Phase Separation
Various lyotropic salts can be used to increase the ionic strength of the aqueous solution, thereby inducing phase separation. Among the preferred salts are sodium sulfate and ammonium sulfate, which are lyotropic. Both are used at a concentration well below that which precipitates proteins. For example, in a specific embodiment, a 0.5 M solution of sodium sulfate is added to an equal volume of the extraction solvent/aqueous preparation mixture, resulting in a final concentration of 0.25 M sodium sulfate. This concentration is pufficient to induce phase separation of HFIP and water. Other salts can also be used, provided they achieve the requisite lyotropic activity at a concentration at which they are soluble.
The term "lyotropic activity" is used herein to refer to the structure-forming properties of a lyotropic salt solution. The lyotropic activity is achieved by achieving a sufficient concentration of lyotropic salt to induce phase separation of the organic and aqueous phases. Protein precipitating concentrations of the lyotropic salt are avoided. k "Lyotropic" or "structure-forming" salts, also known as A kosmotropes, promote the ordering of the aqueous solution, thereby excluding organic solutes. If the organic solute is the extraction solvent, phase separation occurs. If it is a protein, the protein is salted out of solution. Good structure-forming salts include sodium or ammonium sulfate, phosphates, citrates, etc. (Washabaugh and Collins, J. Biol. Chem., 261:12477, 1986). (Structure-breaking salts, or chaotropes, include guanidinium hydrochloride, sodium perchlorate, sodium bromide, etc. These have the opposite effect; they drive organic solutes into aqueous solution.) The ionic strength of an aqueous solution is a function of the total number of ions in solution, regardless of whether they are structure-forming or structure-breaking ions. The term "ionic strength" relates to the concentration of a salt. —_
As discussed above, the lyotropic salt can be added as a solid or concentrated liquid, provided that the final lyotropic salt concentration is effective to induce the phase separation.
Preferably, the final ratio of extraction solvent to aqueous phase (which includes the aqueous preparation of biological material and any salt solution) after increasing the lyotropic activity of the mixture is about 1:10 to about 10:1, preferably (and as exemplified infra) about 1:3 to about 3:1, provided that at the lower ratio of extraction solvent to aqueous phase, the final salt concentration is still high enough to induce phase separation.
After increasing the lyotropic activity, the extraction solvent, which now contains any prion protein that was present in the biological material, separates from the aqueous preparation.
The separation process takes a few minutes, and is complete when both phases are clear and discrete separation is observed between } them. Once the two phases are completely separated, the extraction solvent, now containing any prion protein, can be } removed or withdrawn, e.g., by drawing off with a pipette or syringe, or with a separation flask.
The extraction solvent containing any prion protein (termed herein “extract”) can be dried, e.g., by evaporation, by lyophilization, or vacuum centrifugation to yield highly concentrated or dry extract. The extract may contain other components, including cellular lipids, lipid membrane-binding proteins, and other more hydrophobic cellular components. If desired, prion protein can be isolated or purified away from these components, e.g., by hydrophilic interaction chromatography, as exemplified infra, or other chromatographic techniques (cation exchange chromagraphy, gel permeation chromatography, reverse- phase chromatography, and affinity chromatography, e.g., on an antibody column).
Alternatively, the concentrated or dried extractant material can be analyzed directly, as described infra, to detect abnormal prion protein.
Prion Protein Detector; Immunocassays
Various prion protein detection assays, including assays for pelectively detecting abnormal prion protein, are known in the art to be an effective tool for analyzing prion protein. Capillary gel electrophoresis has proven to be an effective analytical tool for abnormal prion protein (Schmerr and Jenny, Electrophoresis, 19:409, 1998). A preferred method is immunoassay, e.g., as described in Schmerr and Jenny, supra. Antiserum described in this reference is specific for abnormal prion protein, as it was found to react in Western blotting with scrapie-infected brain, but not normal brain. Other antisera reactive with prion protein are well known in the art. A preferred immunoassay is a plate }
ELISA (for example, Grathwohl et al., J. Virol. Methods, 64:205, 1997). .
Thus, in some cases, detection of the presence of prion protein, and particularly abnormal prion protein, is based on the biophysical and chemical characteristics of prion protein. These include proteinase resistance (particularly to proteinase K) and digestion profile: (whether with proteolytic enzymes, glucolytic enzymes, chemicals, heat, denaturants, etc.). The effects of such treatments on apparent molecular weight and isoelectric point, and various binding assays, can be evaluated. Proteinase resistance and digestion profile can be detected by chromatography, gel electrophoresis, and other molecular weight-sensitive techniques.
Isoelectric point can be measured using capillary isoelectric focusing (IEF) or gel isoelectric focusing, although capillary IEF is able to measure the prion pI of 3 more effectively than most
; w WO 00/40966 PCT/US00/00457 gels. Furthermore, qualitative determination of overall charge (acidity or basicity) can be determined by ion exchange chromatography. Other biophysical techniques known in the art can also be used to identify prion protein.
Examples of assays for detection of prion protein include apparent molecular weight and isoelectric point of the protein, including after heating, cyanogen bromide cleavage, neuraminidase treatment, etc. (Bolton et al., J. Virol., 53:596, 1985); glycosidase treatment and lectin binding (Somerville and Ritchie,
J. Gen. Virol., 71:883, 1990); proteinase-K resistance (Race et al., Am. J. Vet. Res., 53:883, 1992); and immunoassay (Farquhar et al., J. Virol. Methods, 24:215, 1989).
Alternatively, sequencing or microsequencing of the extracted, and preferably purified, prion protein permits one to unambiguously confirm its identity. - Immunoassays for prion protein can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA . (enzyme-linked immunosorbant assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), Western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A and protein
G assays, immunoelectrophoresis assays, measuring levels thereof in appropriate physiological samples, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. —_
The extraction method of the invention provides an inexpensive source of prion protein, which can be used to generate additional antibodies. Moreover, because the extraction conditions of the invention differ greatly from conventional extraction conditions, prion protein extracted in accordance with the invention may have a different conformation and elicit a different population of antibodies if used for immunization.
This method shortens the extraction time to 1 to 2 hours.
Moreover, because of its simplicity, it can be automated. The method extracts prion protein of all molecular sizes, so it is not limited. It also solubilizes the abnormal prion protein so that most immunoassays can be used to detect it. Furthermore, and not insignificantly, it reduces the infectivity of the abnormal prion protein, making the process safer.
Kits
The components for practicing the present invention can be conveniently provided in a kit form. In its simplest embodiment, a kit of the invention provides extraction solvent, preferably
HFIP, and lyotropic salt (or a concentrated lyotropic salt polution) for increasing the lyotropic activity of the extraction solvent-aqueous preparation mixture. The amounts of each component can be pre-measured to provide a specified number of assays. In a further embodiment, the kit will include a sample container, preferably of plastic or a material treated to avoid non-specific binding of prion protein.
As used herein, the term container has its broadest meaning, i.e., any receptacle for holding material or reagent. It can be fabricated from glass, plastic, ceramic, metal, or any other material typically employed to hold reagents. However, an
. wv WO 00/40966 PCT/US00/00457 acceptable material will not be reactive with the contents it is intended to hold.
The kit can also include proteinase-K for digesting normal prion protein in the biological sample.
In a further embodiment, the kit includes a sample container with a volume indicator for the aqueous preparation of the biological sample. In this embodiment, the polar organic solvent and the lyotropic salt are optimally provided in pre-measured units for use in conjunction with the sample container. The biological sample preparation can be placed in the sample container. The pre-measured unit of extraction solvent can be added, followed by mixing. Then, the pre-measured unit of lyotropic salt can be added to induce phase separation of the extraction solvent and the water. In still a further embodiment, proteinase-K for treating the aqueous preparation of the } biological sample is provided in the kit, preferably in a pre- measured unit. i A kit for extracting prion protein from a tissue sample may include a dilution buffer, such as a 0.32 M sucrose solution or phosphate buffered saline, for homogenization of the tissue for the aqueous preparation of the biological material.
In a further embodiment, in which the kit is a kit for detecting the presence of abnormal prion protein in a biological material or sample, the kit provides an abnormal prion protein detector or assay, as described above. Immunoassays, as described above, are preferred for detection of abnormal prion protein extracted in accordance with the invention.
In still a further embodiment, the kit includes an immunochromatographic membrane or support. The extraction solvent containing any prion protein can be applied to the support directly, or the dried extract can be applied, e.g., after resolubilization. Under appropriate conditions, prion protein can flow through the support. It may be captured, e.g., by immobilized anti-prion antibody, and immobilized prion protein detected. Numerous methods and devices known in the art for immunochromatographic assays can be employed in the invention.
Immunochromatographic assays are particularly useful under field conditions, where laboratory equipment is not available. Examples of such assays are provided in U.S. Patents No. 5,248,619, No. 5,451,504, No. 5,500,375, No. 5,624,809, and No. 5,658,801.
A kit of the invention preferably includes packaging and instructions for its use, e.g., on the packaging or package insert.
The present invention may be better understood by reference to the following non-limiting Examples, which are provided as exemplary of the invention.
Example 1
Analysis of Abnormal Prion Protein Extracted From Infected Sheep }
Brain and Lymph Nodes.
Brain or lymph node tissue from each of two scrapie infected sheep was homogenized in 10% sarcosyl and treated with proteinase
K to digest the normal host prion protein but not the altered abnormal form of prion protein. Equal volumes (0.5 mM) of homogenate and HFIP were mixed and incubated for five minutes at 56°C. To this mixture, 0.5 mM of 0.5 M Na,S0, were added, and the mixture was incubated an additional five minutes. Under these conditions, the HFIP layer separated from the aqueous layer. The
HFIP layer was drawn off and dried in a centrifuge. The dried samples were resuspended in 25 pl of distilled water and mixed.
Ten pl of the sample was mixed with 5 pul of 20% SDS buffer and, . boiled for five minutes at 100°C.
’ ww WO 00/40966 PCT/US00/00457
Western blot analysis was performed on a 10% to 15% gradient polyacrylamide gel. The protein was transferred from the polyacrylamide gel to nitrocellulose under standard conditions.
The nitrocellulose was blocked by incubation with a solution of 5% fish gelatin, and washed with a Tris-Tween buffer. The nitrocellulose was incubated overnight with a rabbit anti-prion protein (antibody raised against whole prion protein diluted 1 to 2,500; Kascak et al., Immunol. Invest., 26:259, 1997; see also,
Miller et al., J. Vet. Diagn. Invest. 5:309; Kascak et al., J.
Virol., 59:676, 1986). After incubating with the anti-prion antibody, the nitrocellulose was washed with Tris-Tween and then reacted with an anti-rabbit IgG-HRP (horseradish peroxidase) conjugate and incubated for one hour. The nitrocellulose was then washed extensively and developed with a chemiluminescent reagent (Pierce UltraSuperSignal®). Peroxidase activity was detected - using a chemiluminescent imager (Chemi-Imager-4000; Alpha,
Innotech). : Extracts from both scrapie infected sheep containing 2.75 ul of material produced bands indicative of abnormal prion protein for both brain tissue and lymph node tissue. A brain tissue extract containing 1.5 pl of material from one of the scrapie infected sheep also produced a band indicative of abnormal prion protein. A Western blot of similar extracts from normal (noninfected) sheep did not produce any bands indicative of abnormal prion protein.
Example 2
Analysis of Abnormal Prion Protein Extracted and Purified From
Infected Sheep Brain and Lymph Nodes.
This example shows further purification and analysis of . abnormal (scrapie) prion protein (PrPsc) using hydrophilic interaction chromatography (HILIC). Tissue samples including sheep brain and lymph nodes were processed with detergent and proteinase K as previously described. The resulting extracts were applied to a HILIC column and eluted with a decreasing gradient of acetonitrile in 0.1% trifluoroacetic acid and 50 mM hexafluoro- 2-propanol. Recovery from the column was approximately 75% as determined with a radioiodinated prion protein. After drying, the collected peak fractions were resuspended in water and assayed with antibodies specific for the prion protein. The method permitted efficient purification of the prion protein as well as testing by immunoassay, since interfering detergents were removed.
Example 3
Analysis of Abnormal Prion Protein Extracted From Infected Sheep
Brain.
Preparation of sheep brain material. .
Scrapie infected sheep brains were obtained from field cases that were positive for the abnormal prion by Western blot (Race } et al., Am. J. Vet. Res. 53:883, 1992). A pool was made of 3 positive brains. The same pool was used for all the experiments presented here. Normal brains came from sheep from a scrapie-free flock and were negative for abnormal prion protein by Western blot. The brain material was prepared for chromatography by a modification of the method of Bolton et al. (J. Virol. 53:596, 1985). Briefly, the brain stems were dissected out, weighed and placed in 0.32 M sucrose (10% w/v). The material was then homogenized for 60 s with a Brinkman Polytron (Kinematica AG,
Lucerne Switzerland) using a 0.7 cm stainless steel generator at the highest speed. The homogenate was centrifuged at 10,000 g for min to remove particulates, and the resultant supernatant fluid ; was centrifuged at 230,000 g for 1 h. This pellet was then
EE 4 WO 00/40966 PCT/US00/00457 subjected to a series of washes and ultracentrifugations as above.
The sample was treated with 10 mM Tris pH 7.4 containing 10% sodium lauryl sulfate and proteinase K (50 ug/ml). After the final ultracentrifugation, the sample was resuspended in 10 mM
Tris pH 7.4 (200 pul/g of the initial brain sample).
Hydrophilic interaction chromatography (HILIC) .
The sample was solubilized in 0.01 M Tris HCl, pH 8.00 containing 2 mM EDTA, 5% SDS and 10% hexafluoro-2-propanol at 100°C for 10 min. After SDS treatment, the sample was placed in a solvent consisting of 100% acetonitrile containing 0.1% TFA acid and 50 wM hexafluoro-2-propanol (buffer A) and applied to a hydrophilic interaction column. All columns that were used were from PolyLC, Inc. (Columbia, MD, USA) with the dimensions 200 x 4.6-mm; 5 pm; 300-A. Three packings were evaluated, PolyWAX LP™
J (an anion-exchange material), PolyHYDROXYETHYL A™ (a neutral material) and PolySULFOETHYL A™ (a strong cation-exchange : material) (all three trademarks are the property of PolyLC, Inc.).
The flow rate was 0.5 ml/min. The conditions for eluting Prp* were 100% A for 8 min and then a linear gradient to 100% water containing 0.1% trifluoroacetic acid and 50 mM hexafluoro-2- propanol (buffer B) in 15 min, then 100% B for 10 min. Peak fractions were collected and dried in a vacuum centrifuge (Savant
Instruments, Inc, Farmingdale, NY, USA). Fractions were resuspended in 10 pl of deionized H,0 and the fraction that tested positive by immunoblot for PrP* was used in a capillary electrophoresis assay.
Labeling prion protein with *¥I.
PrP*¢ was labeled with ***I using IODOGEN™ (Pierce, Rockford; -
IL, USA). The labeled protein was separated from the free '**I by passing it through a solid phase extraction cartridge containing
PolyWAX LP™(PolyLC, Inc.) that had been equilibrated with buffer
A. The labeled PrP¥ was eluted from the cartridge using buffer
B. The unbound ***I was retained on the cartridge, which could be discarded as solid radioactive waste. The fractions containing the labeled PrP*¢ were dried in a vacuum centrifuge, dissolved in water, diluted 1/10 in buffer A, and loaded onto the HPLC column.
Dot blots.
One-ul aliquots of peak fractions from HILIC chromatography were applied to nitrocellulose paper, dried, and then incubated in 20 mM Tris, pH 7.5, containing 500 mM NaCl, 0.05% Tween 20 (TTBS) and 5% fish gelatin for 1 h. The blot was washed 2x with
TTBS and then incubated with a dilution of 1/500 of antibodies made to peptides of the prion protein for 3 h at 25°C (rabbit antibodies to peptide 142-154). After incubation, the blot was . washed 2x with TTBS and then incubated with biotinylated protein
G (Bio-Rad Laboratories, Hercules, CA, USA) for 1 h. Again the : blot was washed as above. Horseradish peroxidase coupled to
NeutrAvidin™ (Pierce, Rockford, IL, USA) was added to the blot and incubated for 1 h at 25°C. After incubation, the blot was washed 6x with TTBS. After washing, the blot was incubated in the
SuperSignal® Substrate (Pierce) system for 10 min and then exposed to Kodak X-OMAT AR (Eastman Kodak Company, Rochester, NY, USA) X- ray film for 15 sec.
Binding assay for ‘**IPrp*.
Practions containing ***I from the PolyWAX LP column were assayed for binding activity to an antibody that had been produced to the peptide corresponding to residues 142-154 of the prian . protein. The tubes containing radioactivity were dried in a
Ww WO 00/40966 PCT/US00/00457
Savant vacuum centrifuge at 42°C and resuspended in 10 pl of H,0 and then diluted with buffer-containing salts in 0.1% BSA. A PVC plate was coated with the antibody in 0.1 M Na,CO,, pH 9.0. After washing with the above buffer, 100 pl of ***I -PrP* was incubated on the plates at 37°C for 2 h and then overnight at 4°C. The plate was washed and cut into individual wells and counted.
Background cpm were subtracted from the cpm in the wells.
Capillary electrophoresis conditions.
Free zone capillary electrophoresis (Schmerr and Jenny,
Electrophoresis 19:409, 1998) was performed on a Beckman P/ACE 5500 (Beckman Instruments, Fullerton, CA, USA). Laser-induced fluorescence (LIF) detection was done using an air-cooled argon laser (Beckman Instruments) with excitation at 488 nm and emission at 520 nm. Unmodified capillaries were obtained from Beckman
N Instruments. A 20 cm (length to the detector) x 201 um I.D. capillary was used with 200 mM Tricine, pH 8.0. This buffer : contained 0.1% N-octylglucoside (Boehringer Mannheim GmbH,
Indianapolis, IN, USA) and 0.1% BSA (Sigma Chemical Co., St.
Louis, MO, USA). In preparation for the separation, the capillary was rinsed for 1 min with 0.25 M NaOH, rinsed for 2 win with H)0, and then rinsed 2 min with buffer. The separating conditions were 30KV for 3 min at 20°C. The current was about 20 pA. The sample was injected for 15 sec followed by a 5 sec injection of running buffer. The sample volume was about 0.95 nl. Rinses were carried out under high pressure and sample injection carried out under low pressure.
Immune complex and prion binding assays.
Fifteen microliters of fluorescein-labeled peptide containing= - about 2 pmoles of the fluorescent labeled peptide was mixed with affinity-purified rabbit IgG to demonstrate binding of antibody to the fluorescein-labeled peptide. One pl of peak fractions from the HILIC chromatography was added to the assay. After mixing the components, the samples were incubated at 25°C for the 10 min.
Results.
The chromatogram of PrP* after purification and iodination is shown in PIG. 1. Radioactivity (cpm) from the **I-labeled prion protein coincides with the absorbance at 280 nm, except for the last peak detected by absorbance. The yield of abnormal protein, based on recovery of***I cpm loaded onto the column, was about 76%. The peaks of cpm and A280 absorbance coincide with the peaks showing antibody activity in the binding assay (FIG. 2).
The main peak in the binding assay at about 25 min coincides with peaks for **I-PrP and A280 absorbance at 25 min in FIG 1. Similar results were obtained for a chromatogram (not shown) from an . extraction (unpurified) of scrapie infected sheep brains.
A wide range of pI values have been reported in the . literature (Schmerr and Jenny, supra; Safar et al., Proc. Natl.
Acad. Sci. USA 87:6373, 1990; Somerville et al., J. Gen. Virol. 70:25, 1989) for abnormal prion protein. The pl of this protein would affect the binding of this protein to column packings.
There was no great difference between the retention times on the positively-charged PolyWAX LP column and the neutral
PolyHYDROXYETHYL A column. This suggested that the protein might be acidic. Abnormal prion protein samples containing SDS eluted from the negatively-charged PolySULFOETHYL A column in a broad envelope. Accordingly, the abnormal prion protein purified on the
PolyWAX LP column was re-run on the PolySULFOETHYL A column. Its elution in or near the void volume indicates that it is indeed, . acidic. This was confirmed by both gel isoelectric focusing and
: | J WO 00/40966 PCT/US00/00457 capillary electric focusing (Schmerr et al., Chromatogr. A. 802:135, 1998). pl values ranged from 3-6 with a major species at 3.00. These results suggest that in hydrophilic interaction chromatography, it is necessary to use a neutral or an anion exchange material.
In capillary immunoelectrophoresis using HILIC purified samples, resultant electropherograms (not shown) indicate that samples from infected sheep did react, whereas samples from normal (noninfected) sheep did not react. Since SDS inhibits typical immunoassays including capillary electrophoresis assays, it is necessary to remove SDS in order to perform such assays. A competition assay using capillary electrophoresis could be performed on samples after HILIC chromatography, since SDS elutes in or near the void volume (Jend et al., Anal. Biochem., 215:292, 1993).
Example 4 . Analysis of Abnormal Prion Protein Extracted Prom Infected Sheep
Blood.
Buffy coat centrifuge fractions from blood samples from TSE- infected sheep were diluted with Tris buffered saline (10% tissue:90% buffer). The samples were then treated with proteinase
K to digest the normal host prion protein but not the altered abnormal form of prion protein. After digestion, the treated sample was mixed with an equal volume of hexafluoro-2-propanol (HFIP) and incubated at 56°C for five minutes. An equal volume of 0.5 M sodium sulfate was added and the phases were allowed to separate. The layer containing HFIP was removed and the sample dried in a vacuum centrifuge.
The pellet was resuspended in water and the suspension was put in an organic chromatography mobile phase containing 95%
acetonitrile, 5% water, 0.1% trifluoroacetic acid and 50 mM HFIP.
The mobile phase was applied to a solid phase extraction cartridge of PolyHYDROXYETHYL Aspartamide™ (PolyLC, Inc.). Abnormal prion protein was eluted from this support with 100% water, 0.1% trifluoroacetic acid and 50 mM HFIP, and then dried and resuspended in water.
The presence of abnormal prion protein was detected by capillary immunoelectrophoresis. Abnormal prion protein was not detected in electropherograms for control samples of blood that was not infected with TSE.
Example 5
Analysis of Abnormal Prion Protein Extracted From Infected Mule
Deer Blood.
The procedure of Example 4 was repeated with blood samples from TSE-infected mule deer. The presence of abnormal prion . protein was detected by capillary immunoelectrophoresis. Abnormal prion protein was not detected in electropherograms for control } samples of blood that was not infected with TSE.
Example 6
Analysis of Abnormal Prion Protein Extracted From Infected Elk
Blood.
The procedure of Example 4 was repeated with blocd samples from TSE-infected elk. The presence of abnormal prion protein was detected by capillary immunocelectrophoresis. Abnormal prion protein was not detected in electropherograms for control samples of blood that was not infected with TSE.
a. J WO 00/40966 PCT/US00/00457
All patents, patent applications, test protocols, and publications cited herein are hereby incorporated by reference in their entireties. :
The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
N
Claims (26)
1. A method for extracting abnormal prion protein from a biological material suspected of containing abnormal prion protein, said method comprising: (a) incubating a mixture of an extraction solvent and an : isotonic or hypotonic aqueous preparation of biological material under conditions effective to extract abnormal prion protein from said biological material into said extraction solvent, wherein said extraction solvent is; (i) a polar organic solvent in which said abnormal prion protein is soluble, and (11) miscible with a non-lyotropic aqueous solution but immiscible with a lyotropic aqueous solution; and (b) increasing lyotropic activity of the mixture to separate said extraction solvent from said aqueous preparation of said . biological material to yield extraction solvent containing any ’ abnormal prion protein from said biological material.
2. A method as defined in Claim 1, wherein said extraction solvent is hexafluoro-2-propanol.
3. A method as defined in Claim 1, wherein said biological material is a tissue or a biological fluid from a vertebrate.
4. A method as defined in Claim 3, wherein said tissue is brain tissue.
5. A method as defined in Claim 3, wherein said biological fluid is selected from the group consisting of cerebrospinal fluid, blood, plasma, and serum.
. | 4 WO 00/40966 PCT/US00/00457
6 . A method as defined in Claim 3, wherein said biological fluid is human blood.
7. A method as defined in Claim 1, wherein said mixture is incubated at a temperature ranging from about 20°C to about 100°C.
8. A method as defined in Claim 7, wherein said incubation is at about 56°C.
9. A method as defined in Claim 1, wherein said lyotropic activity is increased by adding about a 1:1 ratio (vol/vol) of 0.5 M sodium sulfate to said mixture.
10. A method as defined in Claim 1, wherein said biological material in said isotonic or hypotonic aqueous preparation of ; biological material is treated with proteinase K.
11. A method as defined in Claim 1, further comprising (c) drying the extraction solvent containing abnormal prion protein to yield an extractant pellet.
12. A method as defined in Claim 11, further comprising (d) dissolving said dried extractant pellet in water and purifying said abnormal prion protein.
13. A method as defined in Claim 12, wherein said purifying comprises a method selected from the group consisting of hydrophilic interaction chromatography and capillary electrophoresis.
14. A method for detecting the presence of abnormal prion protein in an animal, said method comprising assaying said separated extraction solvent prepared by a method as defined in Claim 1 for abnormal prion protein.
15. A method as defined in Claim 14 wherein said assay comprises an immunoassay for abnormal prion protein.
16. The method according to Claim 14, wherein the biological sample is a tissue or a biological fluid from a vertebrate.
17. The method according to Claim 16, wherein said tissue is brain tissue.
18. The method according to Claim 16, wherein said biological fluid is selected from the group consisting of cerebrospinal fluid, blood, plasma, and serum.
19. A method as defined in Claim 16, wherein said biological ’ fluid is human blood.
20. A method for extracting abnormal prion protein from a biological material suspected of containing abnormal prion protein, said method comprising: (a) incubating a mixture of about equal amounts of hexafluoro-2-propanol and a non-lyotropic aqueous preparation of biological material under conditions effective to extract abnormal prion protein from said biological material into said hexafluoro- 2-propanol; (b) adding about an equal volume of a solution of 0.5M — sodium sulfate to said mixture to separate said hexafluoro-2-
Ww WO 00/40966 PCT/US00/00457 propanol from said aqueous preparation of said biological material to yield extraction solvent containing any abnormal prion protein from said biological material. :
21. A kit for isolating abnormal prion protein from a biological sample, said kit comprising: (a) an extraction solvent, wherein the extraction solvent is (i) a polar organic solvent in which abnormal prion protein is soluble, and (ii) miscible with a hypotonic or isotonic aqueous solution but immiscible with a lyotropic aqueous solution; and : (b) a lyotropic salt or aqueous lyotropic salt solution to add to an aqueous preparation of a biological sample so that said . organic solvent becomes immiscible with said aqueous preparation.
22. The kit according to Claim 21, further comprising a sample container with a volume indicator for said aqueous preparation of a biological sample, wherein said polar organic solvent and said lyotropic salt or aqueous lyotropic salt solution are provided in pre-measured units for use with said sample container.
23. The kit of Claim 21, further comprising proteinase-K for treating said aqueous preparation of a biological sample.
24. A kit for detecting the presence of abnormal prion protein from a biological sample, said kit comprising (a) an extraction solvent which is —
(i) a polar organic solvent in which abnormal prion protein is soluble, and (ii) miscible with a non-lyotropic aqueous solution but immiscible with a lyotropic aqueous solution; (b) a lyotropic salt or aqueous lyotropic salt solution to add to an aqueous preparation of a biological sample so that said extraction solvent becomes immiscible with said aqueous preparation; and (c) an abnormal prion protein detection assay.
25. The kit according to Claim 24, wherein sald detection assay is an immunoassay.
26. The kit according to Claim 25, wherein said immunoassay ~ is an immunochromatographic assay.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11527299P | 1999-01-08 | 1999-01-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200105304B true ZA200105304B (en) | 2001-12-13 |
Family
ID=27733559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200105304A ZA200105304B (en) | 1999-01-08 | 2001-06-27 | Method and kit for extracting prion protein. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200105304B (en) |
-
2001
- 2001-06-27 ZA ZA200105304A patent/ZA200105304B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU761319B2 (en) | Method and kit for extracting prion protein | |
Schmerr et al. | Use of capillary electrophoresis and fluorescent labeled peptides to detect the abnormal prion protein in the blood of animals that are infected with a transmissible spongiform encephalopathy | |
EP3031823B1 (en) | Method of diagnosing neurodegenerative disease | |
US7462489B2 (en) | Methods for identifying and analyzing biomarkers from plasma-derived microparticles | |
BG65933B1 (en) | Method for diagnosing a transmissible spongiform subacute encephalopathy caused by an unconventional transmissible agent strain in a biological sample | |
KR20010103037A (en) | BLOOD SERUM SAMPLE PREPARED FOR ISOLATION OF PRIONS AND PrPSc | |
Grover et al. | Evidence for the presence of abnormal proteins in the urine of recurrent stone formers | |
ES2270582T3 (en) | PRPRES PURIFICATION PROCEDURE FROM A BIOLOGICAL SAMPLE AND ITS APPLICATIONS. | |
JP2002530650A (en) | Immunoassay for determining infectious spongiform encephalopathy in cattle | |
ZA200105304B (en) | Method and kit for extracting prion protein. | |
EP1135687A1 (en) | An immunoassay for the determination of transmissible spongiform encephalopathies in mammals | |
MXPA01006875A (en) | Method and kit for extracting prion protein | |
BG64291B1 (en) | Method and kit for extracting prion protein | |
JP2004198432A (en) | Detection and diagnosis of transmissible spongiform encephalopathy | |
Sørensen et al. | Multiple isoforms of the human pentraxin serum amyloid P component | |
HUT77340A (en) | Spongiform encephalopathy detection methods | |
KR20230148118A (en) | Method for purification and enrichment of lipid-associated proteins for mass spectrometry analysis of lipid-associated proteins in biological samples | |
US20040175775A1 (en) | Method of detecting PrPsc in eye fluid | |
EP0326547B1 (en) | Reagent kit, its use and diagnostic process for the detection of hpasp (human pancreatic specific protein) | |
WO2013056841A1 (en) | A method for diagnosing tse |